Research programme: farnesoid X receptor modulators - Phenex/Gilead Sciences

Drug Profile

Research programme: farnesoid X receptor modulators - Phenex/Gilead Sciences

Latest Information Update: 09 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Phenex Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Metabolic syndrome; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 05 Jan 2015 Gilead Sciences and Phenex Pharmaceuticals enter into an agreement for Gilead to acquire Phenex's FXR programme of small molecule FXR agonists for the treatment of liver disorders, including non-alcoholic steatohepatitis (NASH)
  • 01 Oct 2013 This programme is still in active development
  • 13 Dec 2005 Preclinical trials in Primary sclerosing cholangitis in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top